Two regulatory storylines underscore mounting pressure on US oversight systems. In one report, BioCentury says FDA used an informal channel to disavow remarks attributed to acting commissioner Robert Makary, leaving drugmakers, investors, and patients without clarity on the agency’s position. Meanwhile, midsize biotechs pressed the White House and HHS to drop pending CMS pricing rules, arguing the models could hinder business operations. The push indicates that reimbursement and interpretation of FDA-adjacent guidance are becoming intertwined risk factors for mid-cap developers planning commercialization and late-stage funding strategies.